Clinical Trials

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Location:

Trial status:

Closed

Why is this study being done?

The purpose of this study is to assess the safety profile of brentuximab vedotin in combination with multi-agent chemotherapy in treatment-naive Stage IIa or IIb-IV Hodgkin lymphoma. It is a phase 1, two-arm, open-label dose escalation study designed to define the maximum tolerated dose, pharmacokinetics, immunogenicity and anti-tumor activity of brentuximab vedotin in combination with frontline therapy.

Who is eligible to participate?

Inclusion Criteria:

- Treatment-naive Hodgkin lymphoma, Stage IIa or IIb-IV

- Measurable disease of at least 1.5 cm

- Eastern Cooperative Oncology Group performance status <3

Exclusion Criteria:

- History of another primary malignancy that has not been in remission for at least 3 years

- Known cerebral/meningeal disease

Last updated: 11/07/2012

NCT ID:

NCT01060904